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Much work has recently focused upon the cellular involvement
of the mesangium in glomerular inflammation and fibrosclerosis. A
host of mediators of inflammation have been identified and their
actions studied in mesangial cell cultures [1]. The recent identifi-
cation of functional receptors for prostaglandins (PG) and throm-
boxane A2 (TxA2) in cultured glomerular mesangial cells [2, 3] has
prompted us and others to examine the relevance of these arachi-
donate (AA) metabolites to mesangial pathophysiology. We inves-
tigated whether exogenous eicosanoids (that is, 20°C atoms unsat-
urated lipids), in addition to their contractile (PGF2, TxA2) or
relaxant (PGE2, PGI2) effects on mesangial cells, affect protein
synthesis and growth rates in culture. The implications of such
effects would be severalfold. First, AA metabolism occurs in
normal glomerular cells, both in culture and in vivo [4]. Binding of
prostanoids to mesangial or neighboring glomerular cells may
modulate their functional behavior. Leukocytes and platelets also
express functional receptors for AA metabolites, and may hence
be recruited by and respond to such diffusible mediators. Second,
AA metabolism is enhanced by vasoconstrictors, cytokines and
growth factors released at the site of inflammation [5, 6]. This
may, in turn, regulate the activity of these primary agents on target
cells. Unlike growth factors or cytokines, the release of pros-
tanoids can occur within seconds of application of stimuli, not
requiring protein synthesis. In turn, induction of key enzymes in
the metabolism of AA has been described in cytokine-activated
cells. Thus, long-term regulation of prostanoid biosynthesis can
also occur during chronic exposure to inflammatory polypeptide
mediators [6]. Third, pharmacologic manipulation of PG and TxA2
synthesis or binding to cellular targets is well established, unlike
growth factors and cytokines, at present. Several agents can
therefore be employed as tools for dissecting out the relative
contribution of eicosanoids to primary events in the progression of
renal injury, such as glomerular hypertrophy, hypercellularity,
and fibrosclerosis.
Results and discussion
Mesangial cells of rat and human origin can be easily grown
in monolayer culture from glornerular explants, provided that a
sufficient amount (that is, > 10%) of fetal bovine serum (FBS)
is added to the media [1]. Preliminary evaluation of the growth
rates of FBS-stimulated cultures established that rat cells
undergo a cycle of DNA synthesis/division every 36 to 48
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hours, while human cells have a faster growth rate of approxi-
mately 24 hours [7, 8]. Withdrawal of FBS results in a rapid
reduction of [3H]-thymidine ([3H]-TdR) or 5-bromo-2'-deoxy-
uridine/5-fluoro-2 '-deoxyuridine incorporation, reflecting arrest
in the G0!G1 phase of the cell cycle. From here synthesis of
DNA can be reinitiated by addition of FBS or purified mitogens,
resulting in synchronous growth of the cells. We have assessed
in parallel the effects of a stable ligand for the TxA2 receptor,
the endoperoxide analogue U-46619, on mesangial cell protein
synthesis and growth. Protein synthesis was assessed by means
of incorporation of radiolabeled aminoacids into newly synthe-
sized proteins. [3H]-leucine (1 tCi/ml) or [35S]-methionine (15
sCi/ml) were used as tracers for total protein synthesis and
incorporation into specific, sodium dodecylsulfate-polyacryla-
mide gel electrophoresis (SDS-PAGE)-separated proteins, re-
spectively. As shown in Figure lA, total protein synthesis of
quiescent cells was significantly enhanced during 24 hour
incubations with 10 n to 1 tM U-46619. Accordingly, [3H]-
TdR (1 Ci/ml) incorporation into DNA was dose-dependently
stimulated by U-46619, with maximal effects at 1 tM. The
effects of U-46619 were prevented by a specific blocker of TxA2
receptors, SQ 27,427 [8]. Although far less potent than FBS or
purified peptide growth factors at comparably high concentra-
tions, the TxA2 analogue was indeed capable of initiating such
cellular events as protein synthesis and DNA duplication, in the
presence of insulin (5 g/ml) as the only added cofactor. On the
other hand, the behavior of protein synthesis and DNA synthe-
sis in cells stimulated with FBS in the presence of U-46619 was
opposite, with a clear additive effect on protein synthesis, while
FBS-stimulated growth was inhibited (Fig. 1B). Cell count
experiments reflected this pattern [8]. The observation is inter-
esting, since it indicates that TxA2 may reduce the proliferative
effects of serum, while inducing protein synthesis, that is,
cellular hypertrophy and/or matrix deposition. In further stud-
ies, 1- and 2-D SDS-PAGE on [35S]-methionine-labeled cells
showed that the effects of U-46619 on protein synthesis are
highly selective, as indicated by specific stimulation of proteins
of molecular wt 35 to 50 and 125 to 200 kD. On the contrary, the
majority of membrane-associated, cytosolic or extracellularly
released proteins were unaffected by treatment of quiescent
cells for up to 24 hours (Fig. 2). These observations are in
agreement with the data by Klotman and associates, who
described the specific induction of multiple mRNA transcripts
for collagen type IV, fibronectin and laminin in human mesan-
gial cells treated with U-46619 [9].
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Fig. 1. Effects of increasing concentrations of
the TxA2 mimetic, U-46619, on [3HJ-thymidine
(A—A) or 13H]-leucine incorporation(• •) into quiescent (A) or proliferating
(B) mono/ayers of cultured human mesangial
cells; N = 8 to /2 experiments. 24-hrs
incubation with U-46619 or vehicle (control,
CTR).
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Fig. 2. Effects of 24 hour incubation with I U-46619 (t) or vehicle
(c) on protein synthesis of quiescent (-fetal bovine serum, FBS)
confluent mono/ayers of cultured human mesangial cells labelled for 4
hrs with 15 p.CiImI [35S]-methionine. Representative SDS-PAGE of
membrane (m) or cytosolic (c)-enriched fractions, obtained by sequen-
tial centrifugation of cell homogenates; N = 8 experiments. Note
selectively enhanced labelling in protein bands marked by arrows.
Molecular weight standards are on sides of each gel.
These findings raise several problems. First, is the effect of
high concentrations of vasoactive prostanoids relevant to the in
vivo situation? In general, there seems to he agreement be-
tween data obtained in studies of different biologic responses,
that is. cell contraction, phosphoinositide metabolism, cyclic
nucleotides, intracellular free Ca2 ([Ca2]), Na/H ex-
change, that TxA2 analogs/mimetics exert stimulatory effects at
concentrations in excess of 10 n.'t [2, 31. This is apparently well
above tissue levels in any biologic system assayed. However, it
200 does not mean that TxA2 lacks bioactivity in vivo, since sizable
amounts of its metabolites have been detected in the urine of
patients with lupus nephritis, and amelioration of renal hemo-
116 dynamics promptly followed TxA2 receptor blockade by con-
tinuous infusion of a specific antagonist [101. Moreover, cells in
culture may express only a fraction of the receptors that exist in
66 vivo, or decrease their affinity for exogenous prostanoids.
Downregulation of the receptors may in part occur because of
release of the autologous ligand by the cells themselves [4]. The
exogenous ligand may also have less affinity than the native,
43 unstable substance. Finally, it is conceivable that the concen-
trations of prostanoids reached at or nearby the site of release
are sufficient to locally saturate the membrane receptors. Tissue
31 or circulating levels are of difficult appreciation for this class of
bioactive lipids, since TxA2 and PG are continuously synthe-
sized, have an extremely short life span, and inactive metabo-
lites tend to accumulate in body fluids.
Second, does PG and TxA2 synthesis by intrinsic mesangial
cells play a regulatory role on cell function, at least in culture?
The issue has been addressed by several investigators, some-
times with conflicting results. Studies in extrarenal fibroblasts
or smooth muscle cells have assigned a major role to endoge-
nous AA metabolites in the regulation of cellular cyclic nude-
otide levels and cell growth. The mitogenic effect of interleu-
kin-I on vascular smooth muscle cells was greatly enhanced by
cyclooxygenase inhibition [11]. In contrast, indomethacin in-
hibited the cyclic AMP and proliferative response to platelet-
derived growth factor (PDGF) in 3T3 fibroblasts, implying a
permissive role of PG-stimulated cyclic nucleotides in the
growth of this cell type [12]. PG synthesis inhibition reversed
the antiproliferative effects of endogenous PG production in rat
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mesangial cells [13]. A recent study demonstrated that indo-
methacin or ibuprofen potentiate the mitogenicity of interleu-
kin- lf3 in rat mesangial cells, consistent with potent induction of
cyclooxygenase. and hence AA metabolism by this cytokine
[14].
If endogenous PG were involved in negative modulation of
mesangial proliferation, then application of exogenous PG
should exert inhibitory effects on cell growth. This is indeed the
case for most studies of vasodilator PG. Both PGE2 and PG 12,
in the form of the stable analogue, Iloprost, stimulate cAMP
accumulation and inhibit serum-stimulated growth of rat and
human cells [3, 7, 8, 13—15]. PGE2 was also found to inhibit
proline uptake and total cell protein synthesis [15]. The effect
on cell-associated proteins and extracellular matrix synthesis
appear to be dissociated, since Homma, Ichikawa and Hoover
found stimulation of intrinsic cell protein synthesis by PGE2,
along with inhibition of matrix deposition [13]. Of interest, the
effects of vasodilator eicosanoids on proliferating cells could be
duplicated with the vasoconstrictor TxA2 mimetic, U-46619,
which characteristically employs different signal transduction
mechanisms, namely phospholipase C activation and elevation
of [Ca2 ] [2, 8]. This suggests that all cyclooxygenase metab-
olites inhibit serum-stimulated DNA synthesis at steps distal of
their apparent transmembrane signals, or that other intracellu-
lar mechanisms account for their actions in cultured cells. It
should be noted that the apparent paradox of stimulation of
proliferation of quiescent cells and inhibition of serum-stimu-
lated growth by U-46619 is reminiscent of previous reports on
the effects of PGEJ in vascular smooth muscle cells [16].
Indeed, the importance of position in the cell cycle should be
emphasized when analyzing the effects of prostanoids. For
practical reasons, both the situation of quiescent cells and of
proliferating cells are relevant to glomerular pathophysiology;
while the majority of mesangial cells undergo a rather slow
turnover under normal conditions [1], during inflammation the
release of growth factors and cytokines is likely to trigger
proliferation of resident glomerular cells.
In conclusion, given the complex and interactive effects of
eicosanoids, which per se have only weak mitogenic or anti-
mitogenic activity, it is prudent to consider these agents as
modulators of proliferation, and evaluate their relationship with
other primary stimuli of cell growth. The relative importance of
eicosanoids in normal and deranged proliferation of kidney
cells, as well as the potential for pharmacological intervention,
will only be appreciated after careful examination of all of these
variables in vitro and in vivo.
Reprint requests to Paolo Menè, M.D., Cattedra di Nefrologia, 2a
Clinica Medica, Policlinico Umberto I, Viale del Policlinico, 00161
Rome, Italy.
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